Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years. The survival for GBM has increased in the last decade but is still low with a median survival of 15-18 months. Recurrence after initial standard therapy, radiation therapy and chemotherapy with temozolomide, few options are available. Even with further therapy, median progression free survival at 6 months after first relapse (PFS-6) is only 15%. Similarly, anaplastic astrocytoma and anaplastic oligodendroglioma, grade III gliomas, once recurrent after radiation therapy and first-line chemotherapy, have identical therapeutic options and poor outcomes with PFS-6 of 31%. Temozolomide (TMZ) has a favorable side effect profile and is available orally, however, cytotoxicity occurs. Metronomic temozolomide at low doses on a continuous schedule, have demonstrated better survival in studies. This study will determine the recommended dose and the side effects of PCI-24781/Abexinostat with metronomic temozolomide.

开始日期2023-06-26

申办/合作机构

University of Nebraska

[+1]

NCT04498520

/ Withdrawn临床1期IIT

Phase I Trial of Abexinostat Combined With Palbociclib and Fulvestrant in Patients With Antiestrogen Refractory ER+, HER2- Breast Cancer and Gynecological Metastatic Tumors

This phase I trial investigates the side effects and best dose of abexinostat and palbociclib when given together with fulvestrant in treating patients with breast or gynecologic cancer. Abexinostat may prevent tumor cells from growing and multiplying and may kill tumor cells. Palbociclib may prevent or slow the growth of tumor cells when used with other anti-hormonal therapy. Estrogen can cause the growth of breast and gynecologic tumor cells. Fulvestrant may help fight breast or gynecologic cancer by blocking the use of estrogen by the tumor cells. Giving abexinostat, palbociclib, and fulvestrant may work better in treating patients with breast or gynecologic cancer.

开始日期2021-03-31

申办/合作机构

The University of California, San Francisco

[+2]

100 项与甲苯磺酸艾贝司他相关的临床结果

登录后查看更多信息

100 项与甲苯磺酸艾贝司他相关的转化医学

登录后查看更多信息

100 项与甲苯磺酸艾贝司他相关的专利（医药）

登录后查看更多信息

125

项与甲苯磺酸艾贝司他相关的文献（医药）

2024-12-05·LEUKEMIA & LYMPHOMA

A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma

Article

作者: Zhu, Menglei ; Bantilan, Kurt S. ; Zelenetz, Andrew D. ; Kumar, Anita ; Matasar, Matthew ; Joseph, Ashlee ; Salles, Gilles ; von Keudell, Gottfried ; Gurumurthi, Ashwath ; Biggar, Erin ; Castro, Ali ; Hamlin, Paul A.

In this phase 1 study, we hypothesized that the combination of the HDAC inhibitor, abexinostat, with ibrutinib would be safe and efficacious in relapsed and refractory MCL and non-germinal center (non-GCB) dLBCL.The main limitation of this study is the premature closure of the trial resulting in small patient numbers without the planned dose expansion cohort with targeted accrual of 34 patients.Furthermore, three MCL responders were unable to complete the full duration of therapy.The trial was terminated in late 2021 due to the evolving therapeutic landscape for relapsed MCL, such as a shift from ibrutinib to the use of 2nd generation BTK inhibitors and the approval of Brexucabtagene autoleucel CAR-T therapy in third-line therapy for MCL.

2024-12-01·Computational and structural biotechnology journal

Uncovering the potential of APOD as a biomarker in gastric cancer: A retrospective and multi-center study

Article

作者: Wang, Zisong ; Wang, Xuanyu ; Sun, Le ; Xu, Yihang ; Tian, Sufang ; Liu, Xiaoping ; Chen, Hongshan

Gastric cancer (GC) poses a significant health challenge worldwide, necessitating the identification of predictive biomarkers to improve prognosis. Dysregulated lipid metabolism is a well-recognized hallmark of tumorigenesis, prompting investigation into apolipoproteins (APOs). In this study, we focused on apolipoprotein D (APOD) following comprehensive analyses of APOs in pan-cancer. Utilizing data from the TCGA-STAD and GSE62254 cohorts, we elucidated associations between APOD expression and multiple facets of GC, including prognosis, tumor microenvironment (TME), cancer biomarkers, mutations, and immunotherapy response, and identified potential anti-GC drugs. Single-cell analyses and immunohistochemical staining confirmed APOD expression in fibroblasts within the GC microenvironment. Additionally, we independently validated the prognostic significance of APOD in the ZN-GC cohort. Our comprehensive analyses revealed that high APOD expression in GC patients was notably associated with unfavorable clinical outcomes, reduced microsatellite instability and tumor mutation burden, alterations in the TME, and diminished response to immunotherapy. These findings provide valuable insights into the potential prognostic and therapeutic implications of APOD in GC.

2024-12-01·INTERNATIONAL IMMUNOPHARMACOLOGY

Identification of mitochondria-related genes as diagnostic biomarkers for diabetic nephropathy and their correlation with immune infiltration: New insights from bioinformatics analysis

Article

作者: Lin, Haibiao ; Zhang, Qiaoxuan ; Huang, Fei ; Han, Liqiao ; Zhan, Min ; Yan, Qiaofang ; Yan, Jun ; Du, Yuanyuan ; Wu, Junbiao ; Huang, Xianzhang ; Zhang, Pengwei

BACKGROUND:

Diabetic nephropathy (DN) is a common and severe microvascular complication of diabetes. Mitochondrial dysfunction and immune inflammation are important factors in the pathogenesis of DN. However, the specific mechanisms and their intricate interactions in DN remain unclear. Besides, there are no effective specific predictive or diagnostic biomarkers for DN so far. Therefore, this study aims to elucidate the role of mitochondrial-related genes and their possibility as predictive or diagnostic biomarkers, as well as their crosstalk with immune infiltration in the progression of DN.

METHODS:

Based on the GEO database and limma R package, the differentially expressed genes (DEGs) of DN were identified. Mitochondrial-related DEGs (MitoDEGs) were then obtained by intersecting these DEGs with mitochondria-related genes from the MitoCarta 3.0 database. Subsequently, the candidate hub genes were further screened by gene co-expression network analysis (WGCNA), and verified mRNA levels of these genes by real-time quantitative PCR (qRT-PCR) in high-glucose-treated human proximal tubular (HK-2) cells. The verified hub genes were utilized to construct a combined diagnostic model for DN, with its diagnostic efficacy assessed across the GSE30122 and GSE96804 datasets. Additionally, the immune infiltration pattern in DN was assessed with the CIBERSORT algorithm, and the Nephroseq v5 database was used to analyze the correlation between hub genes and clinical features of DN.

RESULTS:

Seven mitochondria-related candidate hub genes were screened from 56 MitoDEGs. Subsequently, the expression levels of six of them, namely EFHD1, CASP3, AASS, MPC1, NT5DC2, and BCL2A1, exhibited significant inter-group differences in the HK-2 cell model. The diagnostic model based on the six genes demonstrated good diagnostic efficacy in both training and validation sets. Furthermore, correlation analysis indicated that EFHD1 and AASS, downregulated in DN, are positively correlated with eGFR and negatively with serum creatinine. Conversely, CASP3, NT5DC2, and BCL2A1, upregulated in DN, show opposite correlations. In addition, spearman analysis revealed that the six hub genes were significantly associated with the infiltration of immune cells, including M1 and M2 macrophages, mast cells, resting NK cells, gamma delta T cells, and follicular helper T cells.

CONCLUSION:

This study elucidated the characteristics of mitochondria-related genes and their correlation with immune cell infiltration in DN, providing new insights for exploring the pathogenesis of DN and facilitating the identification of new potential biomarkers and therapeutic targets.

项与甲苯磺酸艾贝司他相关的新闻（医药）

2025-11-28

·医脉通e招募

9月、10月获批以及申报上市抗肿瘤药物！内有免费用药名额可领取↓↓↓

医脉通e招募｜让新药触手可及 ▍9月、10月获批上市药物 9月-10月获批药物聚焦于EGFR与HER2两个靶向通路，与EGFR通路相关药物共3个（西妥昔单抗、美凡厄替尼、维贝柯妥塔单抗），覆盖单抗、TKI、ADC全形态，从结直肠癌到NSCLC再到鼻咽癌，实现癌种横向扩展。与HER2通路相关药物共2个（博度曲妥珠、美凡厄替尼），ADC与TKI协同，以乳腺癌为主战场，向胃癌、非小细胞肺癌扩展。除此之外，卡马替尼的获批实现了从“一线治疗"到"全线治疗"的重要扩展，取消了既往"未经系统治疗"的限制，使经治患者也能获益。芦康沙妥珠单抗作为全球首个获批肺癌适应症的 TROP2 ADC，目前已是第三个适应症获批，用于治疗经表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗后进展的EGFR突变局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）成人患者。此前获批适应症： ▪乳腺癌：2024年11月，用于既往至少接受过2种系统治疗（其中至少1种治疗针对晚期或转移性阶段）的、不可切除的、局部晚期或转移性、三阴性乳腺癌成人患者。 ▪肺癌：2025年3月，用于表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）和含铂化疗治疗后进展的、EGFR（表皮生长因子受体）基因突变阳性、局部晚期或转移性、非鳞状非小细胞肺癌（NSCLC）成人患者。 *芦康沙妥珠单抗针对非小细胞肺癌项目免费用药项目正在开展↓↓ 免费用药 SKB264联合帕博利珠单抗对比化疗联合帕博利珠单抗一线治疗PD-L1阴性的局部晚期或转移性非鳞状非小细胞肺癌患者的临床研究研究用药：试验组：SKB264（芦康沙妥珠单抗）+ 帕博利珠单抗对照组：培美曲塞 + 卡铂/顺铂 + 帕博利珠单抗基本入选条件： 1. 年龄18-75岁，体能状态良好； 2. 转移性（Ⅳ期）的肺腺癌； 3. 已知的驱动基因阴性（EGFR敏感突变阴性、ALK融合基因阴性，且无已知的ROS1 基因融合、NTRK 基因融合、BRAF V600E 突变等已经有获得批准的靶向治疗的驱动基因改变）； 4. 已知PD-L1表达阴性（TPS ＜1%）； 5. 既往未接受针对局晚期或转移性非小细胞肺癌的系统性抗肿瘤治疗。研究所在地区：全国多中心点击申请临床免费用药 ▍9月、10月申报上市药物 *为首次申报上市药物安尼妥单抗（KN026）是康宁杰瑞利用其专有技术平台自主研发的一款抗HER2双特异性抗体，它能够同时结合HER2受体的两个非重叠表位（即ECD4和ECD2），这种双重结合机制带来了多重优势，能更加有效地杀伤肿瘤细胞。安尼妥单抗的申报上市，使其在国内HER2靶向治疗竞争格局中占据了独特且领先的地位，有望成为首个获批上市的国产HER2双抗，并且是首个瞄准HER2阳性胃癌二线治疗的HER2双抗。 *安尼妥单抗针对胃癌项目免费用药项目正在开展↓↓ 免费用药 KN026联合化疗联合或不联合恩朗苏拜单抗对比曲妥珠单抗联合化疗联合或不联合帕博利珠单抗一线治疗 HER2 阳性局部晚期或转移性胃/胃食管结合部腺癌的临床研究研究用药：A组：KN026（安尼妥单抗） + 化疗CAPOX/PF ± 恩朗苏拜单抗 B组：曲妥珠单抗 + 化疗CAPOX/PF ± 帕博利珠单抗 C组：曲妥珠单抗 + 化疗CAPOX/PF ± 恩朗苏拜单抗基本入选条件： 1. 年龄≥18岁，体能状态良好； 2. 诊断为不可切除局部晚期或转移性胃/胃食管结合部腺癌； 3. 未接受过系统治疗； 4. HER2阳性（IHC 2+/FISH 扩增或IHC 3+）。研究所在地区：全国多中心点击申请临床免费用药艾贝司他（Abexinostat）目前处于申报上市审评阶段，针对复发或难治性滤泡性淋巴瘤（r/r FL）适应症已纳入优先审评，r/r FL三线及以上治疗选择匮乏，艾贝司他是首个申报的口服HDAC抑制剂。仑博替尼（Lunbotinib）于2025年9月22日申报上市，用于治疗RET融合阳性局部晚期或转移性非小细胞肺癌（NSCLC）成人患者，是首个申报上市的国产RET抑制剂。布瑞基奥仑赛（Bredcellucel）于2025年9月24日申报上市，用于治疗复发或难治性前体B细胞急性淋巴细胞白血病（r/r B-ALL）成人患者，国内首个申报成人B-ALL的CAR-T产品，填补成人白血病治疗空白。 ▍免费用药持续招募患者中↓↓ 对于家庭经济困难，又缺少治疗方案的患者来讲，参与临床研究本身就是治疗手段之一，目前针对各大肿瘤的项目国内均有开展，我们诚邀您参加，研究项目相关的检查和用药免费，并且在公立三甲医院接受治疗和随诊，有需要的患者可以点击下方报名链接联系我们报名。什么类型的肿瘤患者适合参加临床试验呢？ >当疾病发生进展复查CT或其他影像检查发现原来病灶增大、增多或出现新的转移 >当前方案不耐受 >副作用明显不能继续接受当前方案 >因经济原因放弃治疗点击申请临床免费用药配图来自：视觉中国热门招募回顾，快戳👇 聊聊“临床试验”这个熟悉的“陌生人” 新疗法 | 前列腺癌食管癌治疗项目上新！晚期肺癌没有基因突变？免疫治疗免费用药机会来了三阴性乳腺癌治疗棘手？这种疗法改善显著... EGFR四代靶向药项目上新！不要求测继发靶点！重磅 | 120万一针的CAR-T免费用药机会来了！ 30分钟清零肿瘤细胞？黑科技硼中子俘获疗法有何神奇之处？价格高昂的CAR-T疗法到底是个啥？肝癌、胃癌治疗又有新动向，创新药物进入临床研究复发/难治多发性骨髓瘤患者，CAR-T赠药机会来了！肝癌药物研发新突破助力患者获益众多晚期肝癌患者关注的靶向新药免费了 RET抑制剂免费用药机会来了 7款新药获批临床研究，肺癌患者享受免费用药治疗你和“神药”的距离也许只差这几步参加临床试验免费用药6个注意事项，最后一个道破入组“天机” 消化系统肿瘤创新治疗免费用药方案宫颈癌患者PD-1/CTLA-4双特异性抗体免费用药机会来了 PD-1双抗联合方案为什么会成很多EGFR靶向耐药患者的选择？招募KRAS p.G12C突变的晚期肠癌患者招募HER2阳性晚期非小细胞肺癌患者 CLDN18.2 恶性肿瘤治疗新靶点｜内含免费用药福利三阴性乳腺癌创新治疗方案｜内含免费用药福利 6款血液肿瘤新药获批临床研究免费用药 HER2+乳腺癌患者的新希望！”生物导弹“重拳出击让癌细胞“跪地求饶”! 一代更比一代强：非小细胞肺癌EGFR-TKI是神药？一文读懂 PD-1 抑制剂的不良反应 END 本文由医脉通e招募内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转发授权请在「医脉通e招募」微信公众号留言联系我们。其他合作需求，请联系：ezhaomu@kingyee.com.cn 声明：所有临床试验项目均由国家药品监督管理局(NMPA)以及本研究机构医学伦理委员会批准开展，具备国家药品监督管理局药物临床试验通知书编号可在政府部门公示平台上查询。

2025-09-21

·信狐药迅

两个1类新药：徐诺药业艾贝司他和信立泰泰卡西单抗提交上市申请|新受理（9.15-9.21）

本周药品注册受理数据，分门别类呈现，一目了然。(9.15-9.21）新药上市申请药品名称企业注册分类受理号甲苯磺酸艾贝司他片徐诺药业(南京)有限公司 1 CXHS2500117 泰卡西单抗注射液深圳信立泰药业股份有限公司 1 CXSS2500097 泰卡西单抗注射液深圳信立泰药业股份有限公司 1 CXSS2500096 注射用瑞康曲妥珠单抗苏州盛迪亚生物医药有限公司 2.2 CXSS2500094 新药临床申请药品名称企业注册分类受理号 TQF3250胶囊正大天晴药业集团股份有限公司 1 CXHL2501018 TQF3250胶囊正大天晴药业集团股份有限公司 1 CXHL2501017 TQF3250胶囊正大天晴药业集团股份有限公司 1 CXHL2501016 177Lu-PSMA-VG01注射液山东威智知科药业有限公司 1 CXHL2501015 HRS-6208胶囊山东盛迪医药有限公司 1 CXHL2501014 HRS-6208胶囊山东盛迪医药有限公司 1 CXHL2501013 HRS-6208胶囊山东盛迪医药有限公司 1 CXHL2501012 注射用莱古比星上海亲合力生物医药科技股份有限公司 1 CXHL2501011 HRS-1358片山东盛迪医药有限公司 1 CXHL2501010 HRS-1358片山东盛迪医药有限公司 1 CXHL2501009 冻干带状疱疹病毒mRNA疫苗北京沃森创新生物技术有限公司 1.2 CXSL2500805 冻干带状疱疹病毒mRNA疫苗北京沃森创新生物技术有限公司 1.2 CXSL2500804 靶向CD19基因修饰的异体嵌合抗原受体T细胞注射液上海邦耀生物科技有限公司 1 CXSL2500810 注射用SSGJ-709 沈阳三生制药有限责任公司 1 CXSL2500806 HLX37注射液上海复宏瑞霖生物技术有限公司 1 CXSL2500802 VBC103 上海橙帆医药有限公司 1 CXSL2500801 注射用LBL-047 南京维立志博生物科技股份有限公司 1 CXSL2500797 HX15001注射液华深智药生物科技(苏州)有限公司 1 CXSL2500800 SHR-2906注射液北京盛迪医药有限公司 1 CXSL2500799 QM101细胞注射液北京奇迈永华生物科技有限公司 1 CXSL2500798 LM103注射液苏州蓝马医疗技术有限公司 1 CXSL2500796 JMT206注射液上海津曼特生物科技有限公司 1 CXSL2500795 WGP03 深圳市卫光生物制品股份有限公司 2.2 CXSL2500807 注射用苏维西塔单抗江苏先声生物制药有限公司 2.2 CXSL2500803 仿制药申请药品名称企业注册分类受理号甲苯磺酸艾贝司他片徐诺药业(南京)有限公司 1 CXHS2500117 米诺地尔搽剂海南钧华医疗科技有限公司 3 CYHS2503477 注射用盐酸多西环素湖北美林药业有限公司 3 CYHS2503467 利多卡因丁卡因乳膏江苏盈科生物制药有限公司 3 CYHS2503466 维生素K1注射液江苏九旭药业有限公司 3 CYHS2503464 地氯雷他定口服溶液广州聚力医药开发有限公司 3 CYHS2503469 盐酸奈福泮注射液海南全星制药有限公司 3 CYHS2503457 盐酸苯海拉明注射液四川天杏汇医药科技有限公司 3 CYHS2503453 布瑞哌唑口腔崩解片烟台巨先药业有限公司 3 CYHS2503451 布瑞哌唑口腔崩解片烟台巨先药业有限公司 3 CYHS2503450 盐酸苯海索片云鹏医药集团有限公司 3 CYHS2503445 硝普钠注射液四川奇裕医药科技有限公司 3 CYHS2503444 低钙腹膜透析液(碳酸氢盐-G1.5%) 安徽丰原药业股份有限公司 3 CYHS2503431 低钙腹膜透析液(碳酸氢盐-G2.5%) 安徽丰原药业股份有限公司 3 CYHS2503430 盐酸丁螺环酮片浙江赛默制药有限公司 3 CYHS2503423 盐酸丁螺环酮片浙江赛默制药有限公司 3 CYHS2503422 盐酸丁螺环酮片浙江赛默制药有限公司 3 CYHS2503421 醋酸钙片赤峰固得药业有限公司 3 CYHS2503416 哌柏西利胶囊广州科锐特药业有限公司 4 CYHS2503483 哌柏西利胶囊广州科锐特药业有限公司 4 CYHS2503482 哌柏西利胶囊广州科锐特药业有限公司 4 CYHS2503481 聚乙烯醇滴眼液广州大光制药有限公司 4 CYHS2503480 硫酸氨基葡萄糖胶囊河北九汇医药制造有限公司 4 CYHS2503479 甲磺酸溴隐亭片郑州泰丰制药有限公司 4 CYHS2503478 硫酸氨基葡萄糖胶囊河北三升药业有限公司 4 CYHS2503476 盐酸决奈达隆片石家庄市华新药业有限责任公司 4 CYHS2503475 洛索洛芬钠贴剂北京百奥药业有限责任公司 4 CYHS2503474 洛索洛芬钠贴剂北京百奥药业有限责任公司 4 CYHS2503473 阿帕他胺片重庆华森制药股份有限公司 4 CYHS2503468 富马酸伏诺拉生片广州白云山天心制药股份有限公司 4 CYHS2503465 孟鲁司特钠咀嚼片翎耀生物科技(上海)有限公司 4 CYHS2503463 孟鲁司特钠咀嚼片翎耀生物科技(上海)有限公司 4 CYHS2503462 布瑞哌唑片杭州和泽坤元药业有限公司 4 CYHS2503472 布瑞哌唑片杭州和泽坤元药业有限公司 4 CYHS2503471 硫酸羟氯喹片安若维他药业泰州有限公司 4 CYHS2503470 甲磺酸沙非胺片安徽泰恩康制药有限公司 4 CYHS2503456 甲磺酸沙非胺片安徽泰恩康制药有限公司 4 CYHS2503455 注射用盐酸地尔硫䓬江西科为制药有限公司 4 CYHS2503454 复方氨基酸注射液(18AA-IX) 远大医学营养科学(武汉)有限公司 4 CYHS2503452 复方氨基酸注射液(20AA) 武汉市小铂生物科技有限公司 4 CYHS2503448 吸入用丙酸倍氯米松混悬液四川普锐特药业有限公司 4 CYHS2503447 注射用头孢曲松钠/氯化钠注射液海南倍特药业有限公司 4 CYHS2503446 卡铂注射液广东星昊药业有限公司 4 CYHS2503443 格列齐特缓释片广东彼迪药业有限公司 4 CYHS2503461 甲钴胺片杭州民生药物研究院有限公司 4 CYHS2503460 地塞米松棕榈酸酯注射液汇禹远和(海南)药业有限公司 4 CYHS2503459 苯磺酸左氨氯地平片云鹏医药集团有限公司 4 CYHS2503458 盐酸曲唑酮缓释片福州基石医药科技有限公司 4 CYHS2503449 氨氯地平阿托伐他汀钙片安徽佳和药业有限公司 4 CYHS2503440 聚多卡醇注射液浙江赛默制药有限公司 4 CYHS2503439 聚多卡醇注射液浙江赛默制药有限公司 4 CYHS2503438 注射用氟氧头孢钠苏州二叶制药有限公司 4 CYHS2503437 注射用氟氧头孢钠苏州二叶制药有限公司 4 CYHS2503436 甘油磷酸钠注射液朗天药业(湖北)有限公司 4 CYHS2503432 四烯甲萘醌软胶囊北京柏雅联合药物研究所有限公司 4 CYHS2503429 丁溴东莨菪碱注射液上海理想制药有限公司 4 CYHS2503442 瑞格列奈片重庆药友制药有限责任公司 4 CYHS2503435 硫酸镁钠钾口服用浓溶液河南合智医药科技有限公司 4 CYHS2503434 瑞格列奈片重庆药友制药有限责任公司 4 CYHS2503433 注射用伏立康唑浙江创新生物有限公司 4 CYHS2503441 依折麦布片海南赛立克药业有限公司 4 CYHS2503424 环孢素滴眼液(III) 辅必成(上海)医药科技有限公司 4 CYHS2503420 盐酸氨溴索口服溶液黄山精制药业有限公司 4 CYHS2503419 盐酸氨溴索口服溶液黄山精制药业有限公司 4 CYHS2503418 布洛芬缓释胶囊通化万通药业股份有限公司 4 CYHS2503417 洛索洛芬钠贴剂山东汉方制药有限公司 4 CYHS2503415 洛索洛芬钠贴剂山东汉方制药有限公司 4 CYHS2503414 达格列净二甲双胍缓释片(IV) 山东诺禾康药业有限公司 4 CYHS2503413 苯磺酸美洛加巴林片广州大光制药有限公司 4 CYHS2503412 苯磺酸美洛加巴林片广州大光制药有限公司 4 CYHS2503411 甲苯磺酸艾多沙班片湖南方盛制药股份有限公司 4 CYHS2503410 盐酸米诺环素胶囊成都瑞尔医药科技有限公司 4 CYHS2503409 盐酸米诺环素胶囊成都瑞尔医药科技有限公司 4 CYHS2503408 达格列净二甲双胍缓释片(III) 江苏天士力帝益药业有限公司 4 CYHS2503407 达格列净二甲双胍缓释片(II) 江苏天士力帝益药业有限公司 4 CYHS2503406 达格列净二甲双胍缓释片(I) 江苏天士力帝益药业有限公司 4 CYHS2503405 碘比醇注射液重庆药友制药有限责任公司 4 CYHS2503426 碘比醇注射液重庆药友制药有限责任公司 4 CYHS2503425 麦考酚钠肠溶片山东新时代药业有限公司 4 CYHS2503427 盐酸阿莫罗芬搽剂广州乐宓医药科技有限公司 4 CYHS2503428 人细小病毒B19核酸检测试剂盒(PCR-荧光法) 北京万泰生物药业股份有限公司 CXSS2500095 泰卡西单抗注射液深圳信立泰药业股份有限公司 1 CXSS2500097 泰卡西单抗注射液深圳信立泰药业股份有限公司 1 CXSS2500096 注射用瑞康曲妥珠单抗苏州盛迪亚生物医药有限公司 2.2 CXSS2500094 阿柏西普眼内注射溶液迈威(上海)生物科技股份有限公司 3.3 CXSS2500098 芍药甘草颗粒河北万邦复临药业有限公司 3.1 CXZS2500039 半夏白术天麻颗粒海南斯达制药有限公司 3.1 CXZS2500040 注射用泼尼松龙琥珀酸钠南京恩泰医药科技有限公司 3 CYHL2500173 注射用泼尼松龙琥珀酸钠南京恩泰医药科技有限公司 3 CYHL2500172 注射用泼尼松龙琥珀酸钠南京恩泰医药科技有限公司 3 CYHL2500171 酮洛芬凝胶贴膏福元药业有限公司 3 CYHL2500169 盐酸羟甲唑啉滴眼液海南斯达制药有限公司 3 CYHL2500170 利多卡因丁卡因乳膏西藏中卫诚康药业有限公司 3 CYHL2500168 酮洛芬贴剂上海朝晖药业有限公司 3 CYHL2500167 米诺地尔泡沫剂科笛生物医药(无锡)有限公司 3 CYHL2500166 重组人促卵泡激素注射液成都景泽生物制药有限公司 3.3 CXSL2500809 重组人促卵泡激素注射液成都景泽生物制药有限公司 3.3 CXSL2500808 进口申请药品名称企业注册分类受理号 Gadoquatrane 注射液 Bayer AG 1 JXHS2500103 Gadoquatrane 注射液 Bayer AG 1 JXHS2500102 Gadoquatrane 注射液 Bayer AG 1 JXHS2500101 布地格福吸入气雾剂 AstraZeneca AB 2.4 JXHS2500105 布地格福吸入气雾剂 AstraZeneca AB 2.4 JXHS2500104 氟比洛芬凝胶贴膏 LEAD CHEMICAL CO., LTD. 5.1 JXHS2500106 Gadoquatrane 注射液 Bayer AG 1 JXHS2500103 Gadoquatrane 注射液 Bayer AG 1 JXHS2500102 Gadoquatrane 注射液 Bayer AG 1 JXHS2500101 布地格福吸入气雾剂 AstraZeneca AB 2.4 JXHS2500105 布地格福吸入气雾剂 AstraZeneca AB 2.4 JXHS2500104 氟比洛芬凝胶贴膏 LEAD CHEMICAL CO., LTD. 5.1 JXHS2500106 CVM-1118胶囊 TaiRx, Inc. 1 JXHL2500294 JSB462片 Novartis Pharma AG 1 JXHL2500288 Olomorasib胶囊 Eli Lilly and Company 1 JXHL2500291 Olomorasib胶囊 Eli Lilly and Company 1 JXHL2500290 DZR123片 Novartis Pharma AG 1 JXHL2500289 DZR123片 Novartis Pharma AG 1 JXHL2500287 DZR123片 Novartis Pharma AG 1 JXHL2500286 DZR123片 Novartis Pharma AG 1 JXHL2500285 双醋瑞因软膏 TWi Biotechnology, Inc. 2.2;2.4 JXHL2500293 达罗他胺片 Bayer HealthCare Pharmaceuticals Inc. 2.4 JXHL2500292 DS-3201b片 Daiichi Sankyo, Inc. 2.4 JXHL2500284 吸附无细胞百白破灭活脊髓灰质炎乙型肝炎(重组)和b型流感嗜血杆菌(结合)联合疫苗 Sanofi Winthrop Industrie 3.1 JXSL2500179 注射用AZD0292 AstraZeneca AB 1 JXSL2500182 prasinezumab注射液 F. Hoffmann-La Roche Ltd. 1 JXSL2500181 Tarperprumig注射液 Alexion Pharmaceuticals, Inc. 1 JXSL2500177 AZD4512 AstraZeneca AB 1 JXSL2500176 AZD4512 AstraZeneca AB 1 JXSL2500175 Amivantamab注射液(皮下注射) Janssen Research & Development, LLC 2.2 JXSL2500178 Amivantamab注射液(皮下注射) Janssen Research & Development, LLC 2.2 JXSL2500180 中药相关申请药品名称企业注册分类受理号柴芍解郁颗粒黑龙江省济仁药业有限公司 1.1 CXZL2500084 参苏止咳颗粒玉森(江西)新药研发有限公司 1.1 CXZL2500083 疏肝宁心颗粒中国中医科学院中药研究所 1.1 CXZL2500082 消腺止鼾口服液四川省现代中药创新技术有限公司 1.1 CXZL2500081 玛木然其尼软膏中科中山药物创新研究院 1.1 CXZL2500079 ZHY211贴膏杭州禾橼医药科技有限公司 1.1 CXZL2500078 鼾眠颗粒山东康众宏医药科技开发有限公司 1.1 CXZL2500077 桑枝总生物碱片北京五和博澳药业股份有限公司 2.3 CXZL2500080 芍药甘草颗粒河北万邦复临药业有限公司 3.1 CXZS2500039 半夏白术天麻颗粒海南斯达制药有限公司 3.1 CXZS2500040 注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

疫苗信使RNA临床申请临床1期申请上市

2025-08-20

·PRNewswire

HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast Period (2025-2034) Driven by Innovation in Cancer Therapies | DelveInsight

The HDAC inhibitor pipeline remains active, with several next-generation agents advancing in clinical trials. Abexinostat (Xynomic Pharmaceuticals) is in Phase III development for renal cell carcinoma, representing a potential expansion into solid tumors. Quisinostat (Viriom) is in Phase II for uveal melanoma, and Entinostat, partnered between EOC Pharma and Syndax, is being explored in Hodgkin lymphoma. LAS VEGAS, Aug. 20, 2025 /PRNewswire/ -- DelveInsight's HDAC Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Multiple Myeloma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Amyotrophic Lateral Sclerosis (ALS), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging HDAC inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the HDAC Inhibitors Market Report As per DelveInsight's analysis, the total market size of HDAC inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Multiple Myeloma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Amyotrophic Lateral Sclerosis (ALS), and others. Leading HDAC inhibitor companies, such as Xynomic Pharmaceuticals, Viriom, EOC Pharma, Syndax Pharmaceuticals, Jubilant Therapeutics, and others, are developing novel HDAC inhibitors that can be available in the HDAC inhibitors market in the coming years. Some of the key HDAC inhibitors in the pipeline include Abexinostat, Quisinostat, Entinostat, JBI-802, and others. Discover which indication is expected to grab the major HDAC inhibitors market share @ HDAC Inhibitors Market Report HDAC Inhibitors Overview Histone deacetylases (HDACs) remove acetyl groups from both histone and non-histone proteins. Because acetylation of histones is linked to an open chromatin structure and active gene transcription, HDAC activity leads to histone deacetylation and epigenetic suppression of gene expression. Since HDACs influence many pathways involved in cancer development, HDAC inhibitors (HDACis) show clinical effects through several mechanisms, including changes in gene expression of cell cycle and apoptotic proteins, acetylation of other proteins involved in cell growth and survival, effects on angiogenesis, aggresome formation, and DNA repair. There are 18 known HDACs, divided into two major groups and four classes based on their cellular location, homology, enzyme mechanism, sequence of discovery, and histone substrate specificity. The first group includes zinc-dependent HDACs, which all share a similar catalytic core for deacetylating acetyl-lysine residues. These comprise Class I (HDAC1, -2, -3, -8), Class II (IIa: HDAC4, -5, -7, -9; IIb: HDAC6, -10), and Class IV (HDAC11). The second group includes Class III HDACs (sirtuins, SIRT1–7), which rely on NAD+ for their enzymatic activity. HDAC Inhibitors Epidemiology Segmentation The HDAC inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases of Selected Indications for HDAC Inhibitor Total Eligible Patient Pool of Selected Indications for HDAC Inhibitor Total Treated Cases of Selected Indications for HDAC Inhibitor HDAC Inhibitors Treatment Market Several HDAC inhibitors are currently available on the market. Recent entrants include DUVYZAT (givinostat), while earlier approved drugs include BELEODAQ (belinostat), HIYASTA (tucidinostat), among others. DUVYZAT is a histone deacetylase inhibitor approved for treating Duchenne muscular dystrophy (DMD) in patients aged 6 and above. While it is categorized as an HDAC inhibitor, its exact mechanism of action in DMD is not fully understood. In April 2025, Italfarmaco announced that the CHMP of the European Medicines Agency (EMA) issued a positive opinion on DUVYZAT. The drug is also being evaluated in other indications: Phase III trial in Becker muscular dystrophy (BMD) and Phase II trial in polycythemia vera. HIYASTA (HBI-8000) is an epigenetic immunomodulator approved for several indications, including use as monotherapy for certain subtypes of relapsed or refractory T-cell non-Hodgkin's lymphoma, specifically adult T-cell leukemia-lymphoma (ATLL) and peripheral T-cell lymphoma (PTCL) in Japan. HUYABIO International is conducting a multinational Phase III trial evaluating HIYASTA in combination with nivolumab for previously untreated metastatic or unresectable malignant melanoma. HIYASTA is an oral HDAC Class I inhibitor that induces cell cycle arrest and apoptosis in tumor cells, which underlies its efficacy in lymphoma. In September 2020, the Japanese Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation (ODD) to HIYASTA for relapsed/refractory ATL, and in December 2015 for PTCL. In June 2021, HUYABIO also received regulatory approval in Japan for HBI-8000 as monotherapy for relapsed/refractory ATL. Key Emerging HDAC Inhibitors and Companies Xynomic Pharmaceuticals (Abexinostat), Viriom (Quisinostat), EOC Pharma/Syndax Pharmaceuticals (Entinostat), Jubilant Therapeutics (JBI-802), and several other companies are currently engaged in the development and production of HDAC inhibitors, which have the potential to significantly impact and enhance the HDAC inhibitors market. Abexinostat, an oral, broad-spectrum HDAC inhibitor originally developed by Pharmacyclics and later licensed by Xynomic Pharmaceuticals in 2017, has demonstrated encouraging activity in both blood cancers and solid tumors. The drug is currently being studied in several Phase I to III clinical trials worldwide. In September 2019, Xynomic announced that the FDA had granted Fast Track Designation (FTD) to abexinostat as a monotherapy for fourth-line treatment of relapsed or refractory follicular lymphoma. The FDA had previously granted FTD for abexinostat in combination with pazopanib for first- or second-line therapy in renal cell carcinoma. Additional Phase II trials are underway in indications such as Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma. Quisinostat is another potent, selective oral pan-HDAC inhibitor, initially developed by Janssen Pharmaceuticals. HDAC inhibitors work by inducing cell cycle arrest, promoting differentiation, and triggering apoptosis in various human cancer cell lines. By inhibiting histone deacetylase, they increase acetylation of histone proteins, resulting in a more transcriptionally active chromatin state and altered gene expression involved in proliferation, apoptosis, and differentiation. Multiple preclinical studies and Phase I/II trials have evaluated quisinostat's safety and effectiveness, showing promising anti-tumor effects in several advanced and treatment-resistant cancers — including platinum-resistant ovarian cancer (in combination with paclitaxel and carboplatin), uveal melanoma, and synovial sarcoma. The anticipated launch of these emerging therapies are poised to transform the HDAC inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the HDAC inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about HDAC inhibitors clinical trials, visit @ HDAC Inhibitors Treatment Recent Developments in the HDAC Inhibitors Space In May 2025, Amylyx Pharmaceuticals announced positive Week 48 data from the Phase II open-label HELIOS clinical trial of AMX0035 in adults living with Wolfram syndrome. In May 2025, the University of Miami, in collaboration with Viriom, initiated a Phase II clinical trial in the US (NCT06932757) to evaluate an oral therapy for patients with uveal melanoma who have undergone at least one prior line of treatment. In April 2025, Xynomic Pharmaceuticals concluded a Phase I/II clinical trial in the United States (NCT03939182), evaluating a combination oral therapy for patients with Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma who had received at least one prior line of treatment. Discover more about HDAC inhibitors in development @ HDAC Inhibitors Clinical Trials HDAC Inhibitors Market Dynamics HDAC inhibitors are a class of epigenetic drugs that modify gene expression by altering chromatin structure. Initially developed as anticancer agents, they have shown significant therapeutic potential in various malignancies, especially hematologic cancers like T-cell lymphoma and multiple myeloma. The market initially gained traction with FDA approvals of drugs such as Vorinostat, Romidepsin, and Panobinostat. Their unique mechanism of action targeting epigenetic regulation drew interest as precision medicine and oncology research grew, driving pharmaceutical investment in this segment. The HDAC inhibitors market continues to expand largely due to the rising prevalence of cancer worldwide and the need for more targeted therapies with better safety profiles. Additionally, ongoing clinical trials are exploring HDAC inhibitors in combination with other therapies, such as immune checkpoint inhibitors, proteasome inhibitors, and traditional chemotherapeutics. These combination approaches aim to overcome resistance and enhance efficacy, creating more opportunities for market growth. As more data emerges demonstrating synergistic benefits, partnerships between biotech startups and large pharmaceutical firms are accelerating further development. Despite this positive outlook, the market faces several challenges. Many HDAC inhibitors are associated with toxicity issues such as fatigue, gastrointestinal disturbances, and thrombocytopenia, which limit broader adoption. Competition from newer targeted therapies and immuno-oncology drugs also puts pressure on the HDAC inhibitor segment. Moreover, several compounds failed in late-stage trials due to a lack of efficacy, leading to cautious investor sentiment and prioritization of combination rather than monotherapy approaches. Looking ahead, the market dynamics are expected to be shaped increasingly by precision oncology trends and biomarker-driven patient selection, allowing more effective targeting of responders. If safety profiles can be improved and combination regimens continue to show strong results, HDAC inhibitors will retain a meaningful role in the evolving oncology landscape. Novel formulations, selective HDAC isoform inhibitors, and expansion into non-oncology indications such as neurodegenerative or inflammatory diseases may further diversify the market and drive its next phase of growth. Learn more about the HDAC inhibitors @ HDAC Inhibitors Analysis Scope of the HDAC Inhibitors Market Report HDAC Inhibitors Therapeutic Assessment: HDAC Inhibitors' current marketed and emerging therapies HDAC Inhibitors Market Dynamics: Conjoint Analysis of Emerging HDAC Inhibitor Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, HDAC Inhibitors Market Access and Reimbursement Table of Contents Related Reports Multiple Myeloma Market Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Sanofi, Karyopharm Therapeutics, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., among others. Amyotrophic Lateral Sclerosis Market Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ALS companies, including AB Science, Alector, GSK, Brainstorm Cell Therapeutics, Ionis Pharmaceuticals, Medicinova, Denali Therapeutics, AbbVie, Calico Life Sciences, Clene Nanomedicine Biosciences, Seelos Therapeutics, Prilenia Therapeutics, Rapa Therapeutics, Neurosense Therapeutics, Helixmith, Transposon Therapeutics, Revalesio Corporation, Annexon Biosciences, Corcept Therapeutics, AL-S Pharma, Sanofi, Denali Therapeutics, Orphai Therapeutics, among others. Peripheral T-cell Lymphoma Market Peripheral T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PTCL companies, including Secura Bio, Shanghai YingLi Pharmaceutical, Dizal Pharmaceuticals, Viracta Therapeutics, Innate Pharma, CStone Pharmaceuticals, Affimed, Otsuka Pharmaceutical, Astex Pharmaceuticals, Autolus, Myeloid Therapeutics, Merck Sharp & Dohme, Bristol Myers Squibb, among others. Cutaneous T-cell Lymphoma Market Cutaneous T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CTCL companies, including Pfizer, Helsinn Therapeutics, Kyowa Hakko Kirin, Citius Pharmaceuticals, Soligenix, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, BioInvent International AB, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床3期快速通道孤儿药免疫疗法

100 项与甲苯磺酸艾贝司他相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10060	甲苯磺酸艾贝司他	-	DB12565

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期肾细胞癌	临床3期	美国	-	2018-10-12
局部晚期肾细胞癌	临床3期	中国	-	2018-10-12
局部晚期肾细胞癌	临床3期	捷克	-	2018-10-12
局部晚期肾细胞癌	临床3期	法国	-	2018-10-12
局部晚期肾细胞癌	临床3期	意大利	-	2018-10-12
局部晚期肾细胞癌	临床3期	波兰	-	2018-10-12
局部晚期肾细胞癌	临床3期	韩国	-	2018-10-12
局部晚期肾细胞癌	临床3期	西班牙	-	2018-10-12
局部晚期肾细胞癌	临床3期	英国	-	2018-10-12
转移性肾细胞癌	临床3期	美国	-	2018-10-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04024696 (Pubmed \| BMC Cancer)	临床1期	B细胞淋巴瘤	12	Abexinostat 40 mg BID	範觸蓋淵網夢鏇網鬱製(顧範網鑰構襯築顧襯築) = 鑰築願簾蓋築繭艱顧繭襯襯觸窪壓築淵獵鹹遞 (艱鹹鹹構夢齋齋襯願顧, 7.33 ~ NE) 更多	积极	2025-05-30
				Abexinostat 60 mg BID	範觸蓋淵網夢鏇網鬱製(顧範網鑰構襯築顧襯築) = 壓糧範廠繭壓觸簾鏇糧襯襯觸窪壓築淵獵鹹遞 (艱鹹鹹構夢齋齋襯願顧, 7.33 ~ NE) 更多
NCT03939182 (NEWS) 人工标引	临床1期	套细胞淋巴瘤	-	艾贝司他，伊布替尼	範網網膚齋夢蓋醖顧淵(觸齋廠構簾窪構製遞願) = 艾贝司他联合伊布替尼有效率（CR和ORR）及无进展生存期（PFS）均优于单独使用伊布替尼選顧鏇餘遞鬱製憲窪齋 (壓廠鏇窪窪壓窪構鹽醖 )	积极	2024-06-28
				伊布替尼
NCT03934567 (ASCO2024) 人工标引	临床2期	滤泡性淋巴瘤三线	90	Abexinostat 80 mg BID	蓋餘餘獵鬱餘糧醖鏇齋(製艱築鏇築築鹽醖醖製) = 艱繭夢艱製選鏇遞蓋範壓窪網夢齋鑰鬱齋鹹憲 (窪鬱壓簾獵憲選夢艱齋, 55.8 ~ 77.1) 更多	积极	2024-05-24
				Abexinostat 80 mg BID (pts with > 3 lines of prior therapy)	蓋餘餘獵鬱餘糧醖鏇齋(製艱築鏇築築鹽醖醖製) = 廠艱顧餘餘鏇構蓋廠構壓窪網夢齋鑰鬱齋鹹憲 (窪鬱壓簾獵憲選夢艱齋, 49.2 ~ 84.7)
NCT01543763 (Corporate Publications) 人工标引	临床1期	实体瘤	43	艾贝司他+Pazopanib Hydrochloride (HDAC2高表达)	鬱鏇襯齋艱膚構鑰衊願(齋鬱餘憲醖艱廠願願顧) = 鬱衊觸衊蓋顧繭範淵齋鑰艱顧淵窪蓋遞襯窪齋 (餘網遞齋簾遞襯製觸憲 ) 更多	积极	2022-06-09
				艾贝司他+Pazopanib Hydrochloride (HDAC2低表达)	鬱鏇襯齋艱膚構鑰衊願(齋鬱餘憲醖艱廠願願顧) = 淵鑰觸遞艱鬱鏇範網積鑰艱顧淵窪蓋遞襯窪齋 (餘網遞齋簾遞襯製觸憲 ) 更多
NCT03934567 (ASCO2022) 人工标引	临床2期	难治性滤泡性淋巴瘤	41	abexinostat	遞膚簾網艱憲襯廠糧鏇(艱顧遞製蓋顧餘窪簾範) = 構鏇鹹襯鬱積獵夢膚築夢窪夢夢鹽蓋糧憲餘選 (鹽衊範餘遞鏇齋遞顧壓 ) 更多	积极	2022-06-02
NCT01543763 (ASCO2022) 人工标引	临床1期	恶性实体肿瘤	51	pazopanib+abexinostat (dose escalation)	襯廠顧廠衊膚繭餘壓醖(憲簾廠鬱艱蓋淵網糧衊) = 窪範積蓋鏇艱鏇鬱壓簾製襯鬱築積鑰齋選築糧 (鏇遞繭範襯齋鏇網鏇鹽 )	积极	2022-06-02
				pazopanib+abexinostat (RCC + dose expansion)	襯廠顧廠衊膚繭餘壓醖(憲簾廠鬱艱蓋淵網糧衊) = 鹽積繭獵鹹積簾糧襯願製襯鬱築積鑰齋選築糧 (鏇遞繭範襯齋鏇網鏇鹽 )
NCT01543763 (ASCO 12019 \| ASCO 22019) 人工标引	临床1期	实体瘤 \| 肾细胞癌二线	51	abexinostat+pazopanib	範鏇鹹願觸膚糧積廠築(築網鹹鏇壓製餘糧範齋) = 憲夢衊鹽艱鬱繭製構築齋淵齋鏇構積壓遞憲壓 (製鏇糧襯鏇憲襯遞顧積 ) 更多	积极	2019-05-26
				abexinostat+pazopanib (RCC)	-
AACR2016	临床1期	晚期恶性实体瘤	52	Abexinostat + Pazopanib	積夢製夢鏇餘鑰蓋鏇選(築糧醖鹽簾網簾糧鹽憲) = 10% 夢淵積襯遞願鬱衊膚鑰 (製築願網鹹蓋繭夢醖繭 ) 更多	积极	2016-07-15
NCT01543763 (ASCO2016)	临床1期	晚期恶性实体瘤	52	Abexinostat + Pazopanib	積淵積繭醖觸餘鹽觸膚(鏇鑰淵醖構壓遞憲鏇廠) = The most common grade ≥ 3 related adverse events observed were diarrhea (10%) 壓積餘鏇憲糧觸鏇鹽糧 (壓餘繭獵鑰襯齋蓋範鬱 ) 更多	积极	2016-05-20
NCT01027910 (Pubmed \| Cancer) 人工标引	临床1期	肉瘤	20	doxorubicin+abexinostat (participants received abexinostat 15 mg/m(2) or 30 mg/m(2) twice daily.)	鹽鹽鹽範願製觸繭鬱鑰(範夢簾襯簾鏇鹹範觸網) = DLTs of grade 3 and 4 neutropenia were observed in 2 of 3 participants who received abexinostat 30 mg/m(2) twice daily.Two DLTs were observed at the 60 mg/m(2) twice-daily dose (grade 3 infection, grade 4 thrombocytopenia). 獵膚製選膚積窪鑰觸襯 (範願獵艱夢鬱積鬱構襯 )	积极	2015-04-15
				doxorubicin+abexinostat (participants received abexinostat at doses of 30 mg/m(2), 45 mg/m(2), or 60 mg/m(2) twice daily, all with mandated G-CSF support.)